News | June 26, 2013

New Research Demonstrates Success of Shock Avoidance in Medtronic Defibrillators

"Shock-Less" late breaking clinical trial: providing clinicians with ICD programming reports improves adherence to evidence-based guidelines, reduces shocks

June 26, 2013 — Validating its shock reduction research and technology, Medtronic Inc. announced the results of three clinical trials, Shock-Less, PainFree SST and ADVANCE III, which successfully employed key strategies to dramatically reduce inappropriate and unnecessary shocks in patients with implantable cardiac defibrillators (ICD). The studies followed more than 7,000 patients on six continents; results were presented at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.

ICDs are sophisticated devices designed to provide lifesaving shocks or painless pacing (anti-tachycardia pacing, or ATP) to stop life-threatening fast or irregular heartbeats. While the majority of shocks delivered are necessary to treat potentially fatal arrhythmias, studies estimate that approximately 20 percent of patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device.[1] According to published literature, ICD shocks are associated with increased anxiety for the patient, as well as increased healthcare utilization[1].

The studies demonstrate that a combination of Medtronic-exclusive device algorithms and evidence-based programming strategies allow physicians to safely avoid unnecessary shocks and can reduce the number of patients who receive an inappropriate shock to less than 2 percent per year.

Presented as a late-breaking clinical trial, results of Shock-Less demonstrated that in real-world practice, providing clinicians with reports that displayed ICD parameter settings in relation to evidence-based targets improved adherence to evidence-based shock reduction programming, which was associated with reduced risk of ICD shocks. The reports increased adherence to guidelines by up to 20 percent and reduced the relative risk of a shock by 27 percent. The Shock-Less prospective clinical trial enrolled 4,131 primary and secondary prevention ICD patients between 2009 and 2012 at 118 clinical sites.

"The results of this study are clear: When clinicians followed the evidence-based programming recommendations, the risk of all cause and inappropriate shocks was reduced," said Marc Silver, M.D., lead investigator and cardiologist at WakeMed in Raleigh, N.C. "Establishing methods that improve and maintain clinician adherence to guidelines is therefore crucial to reducing ICD patient morbidity."

Primary results from the PainFree SST clinical trial demonstrated that treating patients with ICDs featuring Medtronic's exclusive SmartShock technology resulted in the delivery of life-saving shocks when needed to save lives, with more than 98 percent of patients free from inappropriate shocks during the first year of implant.

SmartShock Technology features six exclusive algorithms automatically "ON" that recognize life-threatening arrhythmias and deliver therapeutic shocks when appropriate[2], therefore improving patient quality of life.[3] PainFree SST is a multi-center international prospective clinical trial; this analysis encompassed 1,308 patients implanted with dual and triple chamber ICDs.

The Shock-Less and PainFree SST results build on the findings of the ADVANCE III4 (Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III) clinical trial, published in this week's edition of the Journal of the American Medical Association, which demonstrated reduced rate of hospitalizations by 19 percent when devices were programmed to wait longer to deliver therapy to patients, compared to devices with standard programming. ADVANCE III data presented at Heart Rhythm further identified that this prolonged detection also reduced the rate of inappropriate shocks by 45 percent.

"These data show that ICD programming matters, but real world clinical practice suggests that many ICDs are not currently programmed for optimal patient outcomes. By combining best practice programming with proprietary shock reduction technology, Medtronic has made it easier to achieve and sustain the patient outcomes reported in clinical trials with minimal programming changes," said Marshall Stanton, M.D., vice president and general manager, implantable defibrillator business, cardiac rhythm disease management at Medtronic.

For more information: www.medtronic.com

References:

1 Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008 Sep 4;359(10):1009-17. doi: 10.1056/NEJMoa071098.

2 Volosin et. al. "Virtual ICD: A Model to Evaluate Shock Reduction Strategies." Heart Rhythm. Vol. 7, N. 5, May supplement 2010. (PO3-125).

3 Wathen MS, et al. Circulation. 2004; 110:2591-2596.

4 JAMA. 2013;309(18):1903-1911.

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init